BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35795060)

  • 1. Efficacy and Safety of Anlotinib in the Treatment of Small Cell Lung Cancer: A Real-World Observation Study.
    Yuan J; Cheng F; Xiao G; Wang X; Fan H
    Front Oncol; 2022; 12():917089. PubMed ID: 35795060
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
    Gao X; Peng L; Zhang L; Huang K; Yi C; Li B; Meng X; Li J
    J Cancer Res Clin Oncol; 2022 Oct; 148(10):2661-2671. PubMed ID: 34748028
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Efficacy and Safety of Anlotinib in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Zhang R; Ruan ZP; Tian T; Liang X; Yao Y
    Cancer Manag Res; 2022; 14():2273-2287. PubMed ID: 35942069
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness and Safety of Anlotinib Monotherapy for Patients with Extensive-stage Small-Cell Lung Cancer Who Progressed to Chemotherapy: A Real-world Exploratory Study.
    Li Y; Sun Z; Sun W; Wang H; Zu J
    Clin Med Insights Oncol; 2022; 16():11795549211067184. PubMed ID: 35095286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of anlotinib as maintenance therapy after induction chemotherapy in extensive-stage small-cell lung cancer.
    Wang N; Zhao L; Zhang D; Kong F
    Anticancer Drugs; 2023 Apr; 34(4):558-562. PubMed ID: 36728981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhong Q; Liu Z
    Cancer Manag Res; 2021; 13():4115-4128. PubMed ID: 34045898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of ICI plus anlotinib vs. anlotinib alone as third-line treatment in extensive-stage small cell lung cancer: a retrospective study.
    Chen Q; Li Y; Zhang W; Wang C; Yang S; Guo Q
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):401-408. PubMed ID: 34797416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Response to first-line treatment predicts progression-free survival benefit of small-cell lung cancer patients treated with anlotinib.
    Qin B; Xin L; Hou Q; Yang B; Zhang J; Qi X; Wei Y; Hu Y; Xiong Q
    Cancer Med; 2021 Jun; 10(12):3896-3904. PubMed ID: 33960145
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety of Anlotinib Monotherapy as Third-Line Therapy for Elderly Patients with Non-Small Cell Lung Cancer: A Real-World Exploratory Study.
    Jiang HT; Li W; Zhang B; Gong Q; Qie HL
    Int J Gen Med; 2021; 14():7625-7637. PubMed ID: 34754233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance anlotinib improves the survival prognosis of extensive-stage small cell lung cancer: a single-arm, prospective, phase II study.
    Kong F; Wang Z; Wang N; Zhang D; Liao D; Zhang J; Sun Y; Zhang H; Jia Y
    Am J Cancer Res; 2023; 13(8):3679-3685. PubMed ID: 37693149
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer.
    Shao Y; Luo Z; Yu Y; He Y; Liu C; Chen Q; Zhu F; Nie B; Liu H
    Front Oncol; 2022; 12():939343. PubMed ID: 35965587
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy and safety of anlotinib combined with platinum-etoposide chemotherapy as first-line treatment for extensive-stage small cell lung cancer: A Chinese multicenter real-world study.
    Zheng HR; Jiang AM; Gao H; Liu N; Zheng XQ; Fu X; Ruan ZP; Tian T; Liang X; Yao Y
    Front Oncol; 2022; 12():894835. PubMed ID: 36203439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.
    Zhang X; Zeng L; Li Y; Xu Q; Yang H; Lizaso A; Mao X; Jin R; Zeng Y; Li Q; Wang J; Li Y; Zhang Y; Yang N
    Cancer Immunol Immunother; 2021 Sep; 70(9):2517-2528. PubMed ID: 33566148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and Safety of Anlotinib-Containing Regimens in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Sun L; Zhao Q; Wang Y; Wang Y; Zheng M; Ding X; Miao L
    Int J Gen Med; 2023; 16():4165-4179. PubMed ID: 37720175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etoposide/platinum plus anlotinib for patients with transformed small-cell lung cancer from EGFR-mutant lung adenocarcinoma after EGFR-TKI resistance: a retrospective and observational study.
    Ding J; Leng Z; Gu H; Jing X; Song Y
    Front Oncol; 2023; 13():1153131. PubMed ID: 37361601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Zhang K; Ma X; Gao H; Wang H; Qin H; Yang S; Liu X
    Cancer Manag Res; 2020; 12():3409-3417. PubMed ID: 32494205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of Anlotinib Maintenance Therapy in Patients With Advanced NSCLC in a Real-World Setting.
    Li J; Han B; Liu H
    Front Oncol; 2022; 12():785865. PubMed ID: 35847883
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of tumor cavitation in extensive-stage small-cell lung cancer patients treated with anlotinib.
    Chen D; Xu J; Zhao Y; Chu T; Zhong H; Han B; Zhong R
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):401-406. PubMed ID: 31691871
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Study of Anlotinib as Third-Line or Above Therapy in Patients With Advanced or Metastatic Gastric Cancer: A Multicenter Retrospective Study.
    Nie C; He Y; Lv H; Gao M; Gao X; Chen B; Xu W; Wang J; Liu Y; Zhao J; Chen X
    Front Oncol; 2022; 12():885350. PubMed ID: 35860585
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study.
    Liu Y; Ge Q; Xu S; Li K; Liu Y
    Front Oncol; 2022; 12():942678. PubMed ID: 36059654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.